Which high-risk HPV assays fulfil criteria for use in primary cervical cancer screening?
Open accessAbstract
Several countries are in the process of switching to high-risk human papillomavirus (hrHPV) testing for cervical cancer screening. Given the multitude of available tests, validated assays which assure high-quality screening need to be identified. A systematic review was conducted to answer the question which hrHPV tests fulfil the criteria defined by an international expert team in 2009, based on reproducibility and relative sensitivity and specificity compared to Hybrid Capture-2 or GP5+/6+ PCR-enzyme immunoassay. These latter two hrHPV DNA assays were validated in large randomized trials and cohorts with a follow-up duration of 8 years or more. Eligible studies citing the 2009 guideline were retrieved from Scopus (http://www.scopus.com) and from a meta-analysis assessing the relative accuracy of new hrHPV assays versus the standard comparator tests to detect high-grade cervical intraepithelial neoplasia or cancer in primary screening. The cobas 4800 HPV test and Abbott RealTime High Risk HPV test were consistently validated in two and three studies, respectively, whereas the PapilloCheck HPV-screening test, BD Onclarity HPV assay and the HPV-Risk assay were validated each in one study. Other tests which partially fulfil the 2009 guidelines are the following: Cervista HPV HR Test, GP5+/6+ PCR-LMNX, an in-house E6/E7 RT quantitative PCR and MALDI-TOF (matrix-assisted laser desorption-ionization time-of-flight). The APTIMA HPV assay targeting E6/E7 mRNA of hrHPV was also fully…
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Several HPV assays have partially or completely been clinically validated using these criteria.
“Several HPV assays have partially or completely been clinically validated using these criteria [3].”
From Clinical validation of Anyplex™ II HPV HR Detection according to the guidelines for HPV test requirements for cervical cancer screening (2016) · cites this paper as [3]
Anyplex II HPV HR Detection adds to some other validated assays that it directly provides genotyping data of 14 HR HPV types.
“Anyplex TM II HPV HR Detection adds to some other validated assays [3] that it directly provides genotyping data of 14 HR HPV types.”
From Clinical validation of Anyplex™ II HPV HR Detection according to the guidelines for HPV test requirements for cervical cancer screening (2016) · cites this paper as [3]
Based on the findings, Anyplex II HPV HR Detection can be added to the list of HPV assays that fulfill the 2009 guidelines.
“Based on our findings, Anyplex TM II HPV HR Detection can be added to the list of HPV assays that fulfill the 2009 guidelines [3].”
From Clinical validation of Anyplex™ II HPV HR Detection according to the guidelines for HPV test requirements for cervical cancer screening (2016) · cites this paper as [3]
Cites
Ronco, G., Dillner, J., Elfström, K. M., Tunesi, S., Snijders, P. J. F., Arbyn, M., Kitchener, H., Segnan, N., Gilham, C., Giorgi-Rossi, P., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62218-7 · Cited by 1,810 · see citing works
Self-citationComparing the performance of six human papillomavirus tests in a screening population
Cuzick, J., Cadman, L., Mesher, D., Austin, J., Ashdown-Barr, L., Ho, L., Terry, G., Liddle, S., Wright, C., Lyons, D., et al. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.22 · Cited by 211 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Arbyn, M., Smith, S. B., Temin, S., Sultana, F., & Castle, P. (2018) · BMJ · doi:10.1136/bmj.k4823 · Cited by 851 · see citing works
Self-citationVALGENT: a protocol for clinical validation of human papillomavirus assays
Arbyn, M., Depuydt, C., Benoy, I., Bogers, J., Cuschieri, K., Schmitt, M., Pawlita, M., Geraets, D., Heard, I., Gheit, T., et al. (2016) · Journal of Clinical Virology · doi:10.1016/j.jcv.2015.09.014 · Cited by 157 · see citing works
Self-citationHesselink, A. T., Sahli, R., Berkhof, J., Snijders, P. J. F., van der Salm, M. L., Agard, D., Bleeker, M. C. G., & Heideman, D. A. M. (2016) · Journal of Clinical Virology · doi:10.1016/j.jcv.2016.01.009 · Cited by 61 · see citing works
Self-citationCuschieri, K., Geraets, D., Cuzick, J., Cadman, L., Moore, C., Vanden Broeck, D., Padalko, E., Quint, W., & Arbyn, M. (2016) · Journal of Clinical Microbiology · doi:10.1128/jcm.00897-16 · Cited by 55 · see citing works
Self-citationKellen, E., Benoy, I., Vanden Broeck, D., Martens, P., Bogers, J., Haelens, A., & Van Limbergen, E. (2018) · International Journal of Cancer · doi:10.1002/ijc.31391 · Cited by 48 · see citing works
Assessment of the Roche Linear Array HPV Genotyping Test within the VALGENT framework
Xu, L., Oštrbenk, A., Poljak, M., & Arbyn, M. (2018) · Journal of Clinical Virology · doi:10.1016/j.jcv.2017.12.001 · Cited by 45 · see citing works
Self-citationOštrbenk, A., Xu, L., Arbyn, M., & Poljak, M. (2018) · Journal of Clinical Microbiology · doi:10.1128/jcm.01176-18 · Cited by 34 · see citing works
Self-citationAdsul, P., Srinivas, V., Gowda, S., Nayaka, S., Pramathesh, R., Chandrappa, K., Khan, A., Jayakrishna, P., & Madhivanan, P. (2019) · International Journal of Gynecology & Obstetrics · doi:10.1002/ijgo.12859 · Cited by 23 · see citing works
- Authors
- Arbyn, M., Snijders, P. J. F., Meijer, C. J. L. M., Berkhof, J., Cuschieri, K., Kocjan, B. J., & Poljak, M.
- Affiliations
- Institut Scientifique de Santé Publique (BE)
- Amsterdam UMC Location Vrije Universiteit Amsterdam (NL)
- Edinburgh Royal Infirmary (GB)
- University of Ljubljana (SI)
- Corresponding author
- Arbyn, M.
- Venue
- Clinical Microbiology and Infection
- Publisher
- Elsevier BV
- Published
- 2015-09
- Volume
- 21
- Issue
- 9
- Pages
- 817-826
- ISSN
- 1198-743X (ISSN-L)
- OpenAlex
- W1998567451
- Cited by
- 275
- References
- 2
- Citations by year
- 2026: 8 · 2025: 5 · 2024: 20 · 2023: 15 · 2022: 21 · 2021: 27 · 2020: 28 · 2019: 36 · 2018: 37 · 2017: 21 · 2016: 39 · 2015: 17
- FWCI
- 29.82
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Clinical Microbiology and Infection (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
- Pure Amsterdam UMC (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Topics
- Health Sciences › Medicine › Epidemiology › Cervical Cancer and HPV Research
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Women's cancer prevention and management
- Life Sciences › Immunology and Microbiology › Microbiology › Reproductive tract infections research
- Keywords
- high-risk HPV testing, cervical cancer screening, assay validation, Hybrid Capture 2, Cobas 4800 HPV test, Aptima HPV assay, E6/E7 mRNA, high-grade cervical intraepithelial neoplasia, assay sensitivity and specificity, MALDI-TOF mass spectrometry, screening frequency
- MeSH terms
- Uterine Cervical Neoplasms, Female, Humans, Sensitivity and Specificity, Reproducibility of Results, Molecular Diagnostic Techniques, Papillomaviridae, Early Detection of Cancer, Genotyping Techniques
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
